|
Blood and lymphatic system disorders
|
|
Hypertension
|
3 (16.7)
|
1 (5.6)
|
2 (11.1)
|
0
|
0
|
6 (33.3)
|
|
Vaginal hemorrhage
|
2 (11.1)
|
0
|
0
|
0
|
0
|
2 (11.1)
|
|
Endocrine disorders
|
|
Hypothyroidism
|
7 (38.9)
|
0
|
0
|
0
|
0
|
7 (38.9)
|
|
Metabolism and nutrition disorders
|
|
Hypertriglyceridemia
|
5 (27.8)
|
1 (5.6)
|
0
|
0
|
0
|
6 (33.3)
|
|
Decreased appetite
|
0
|
2 (11.1)
|
0
|
0
|
0
|
2 (11.1)
|
|
Respiratory, thoracic, and mediastinal disorders
|
|
Dysphonia
|
2 (11.1)
|
0
|
0
|
0
|
0
|
2 (11.1)
|
|
Gastrointestinal disorders
|
|
Nausea
|
4 (22.2)
|
0
|
0
|
0
|
0
|
4 (22.2)
|
|
Abdominal pain
|
2 (11.1)
|
0
|
0
|
0
|
0
|
2 (11.1)
|
|
Diarrhea
|
2 (11.1)
|
1 (5.6)
|
0
|
0
|
0
|
3 (16.7)
|
|
Mouth ulceration
|
1 (5.6)
|
1 (5.6)
|
0
|
0
|
0
|
2 (11.1)
|
|
Renal and urinary disorders
|
|
Proteinuria
|
8 (44.4)
|
0
|
0
|
0
|
0
|
8 (44.4)
|
|
Hematuria
|
7 (38.9)
|
0
|
0
|
0
|
0
|
7 (38.9)
|
|
Skin and subcutaneous tissue disorders
|
|
Rash
|
1 (5.6)
|
1 (5.6)
|
0
|
0
|
0
|
2 (11.1)
|
|
Palmar-plantar erythrodysesthesia syndrome
|
1 (5.6)
|
1 (5.6)
|
0
|
0
|
0
|
2 (11.1)
|
|
General disorders and administration site conditions
|
|
Fatigue
|
7 (38.9)
|
4 (22.2)
|
0
|
0
|
0
|
11 (61.1)
|
|
Lab examinations
|
|
Leucopenia
|
2 (11.1)
|
1 (5.6)
|
0
|
0
|
0
|
3 (16.7)
|
|
ALT increased
|
2 (11.1)
|
0
|
0
|
0
|
0
|
2 (11.1)
|
|
Amylase increased
|
3 (16.7)
|
1 (5.6)
|
0
|
0
|
0
|
4 (22.2)
|
|
Conjugated bilirubin increased
|
5 (27.8)
|
0
|
0
|
0
|
0
|
5 (27.8)
|
|
Neutropenia
|
2 (11.1)
|
0
|
2 (11.1)
|
0
|
0
|
4 (22.2)
|
|
AST increased
|
3 (16.7)
|
0
|
0
|
0
|
0
|
3 (16.7)
|
|
Hyperbilirubinemia
|
2 (11.1)
|
0
|
0
|
0
|
0
|
2 (11.1)
|
|
Unconjugated bilirubin increased
|
2 (11.1)
|
0
|
0
|
0
|
0
|
2 (11.1)
|
|
Blood urea increased
|
2 (11.1)
|
0
|
0
|
0
|
0
|
2 (11.1)
|
|
Thrombocytopenia
|
2 (11.1)
|
0
|
0
|
0
|
0
|
2 (11.1)
|
